// App-Quantinova.ai

2664 : Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Elias Jabbour

Principal Investigators

  • Kantarjian Hagop

  • Deborah A. Thomas

  • Susan -Brien

  • Guillermo Garcia-Manero

  • Daniela Hoehn

  • Rebecca Garris

  • Stefan H. Faderl

  • Jorge Cortes

  • Tapan M. Kadia

  • Farhad Ravandi

  • Srdan Verstovsek

Medical Centers

  • Department of Pathology, Columbia University, New York, NY

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Peripheral Nervous System

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Septic shock

  • Neutropenia

  • Peripheral neuropathy

Biomarkers

  • Breakpoint Cluster Region

  • White Blood Cell

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • 6-mercaptopurine

  • Allmercap

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Asparaginase

  • fludarabine tablet

  • Vincristine

  • Doxorubicin

  • Cytarabine liposomal

  • ofatumumab Intravenous

  • Prednisone

  • Rituximab

  • ara-c

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved